News

Advancements in macular laser therapy, emphasizing standardization, precision delivery, and innovative treatment strategies for retinal conditions.

Harvard researchers used data to shed light on pediatric neurotrophic keratopathy, revealing key insights into prevalence, vision outcomes, and treatment approaches.

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

A recent study reveals significant ocular complications from monkeypox, highlighting the need for enhanced eye health strategies in affected regions.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy.

Explore early MacTel diagnosis with OCT/FA, who qualifies for Encelto implant, and how costs, reimbursement, and surgery shape timely retina care.

For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice.

Positive findings in a gene therapy trial for patients with Leber Congenital Amaurosis Type 5.

The FDA noted in the letter that it is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Oluwatosin U. Smith, MD, highlights the practical impact of expanding tools on real-world glaucoma treatment.

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

Concentric lens positioning of an adjustable lens helps avoid a late myopic shift.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

The year introduced shifts in residency education, and program directors reflect on changes, challenges, and what’s next.

The novel system converts light into electrical signals to stimulate retinal cells.

A shift toward minimally invasive, evidence-based interventions is redefining standards of care.

Sahar Bedrood, MD, PhD; Inder Paul Singh, MD; and AnnMarie Hipsley, DPT, PhD, recount moments that blended professional milestones with mentorship and legacy.

Sezen Karakus, MD, highlights options including compounded cyclosporine, autologous serum drops, recombinant human nerve growth factor, and newer topical agents to manage refractory or neurotrophic dry eye.

An overview of the top 10 stories from Optometry Times in 2025.

Looking back on 2025, Neda Shamie shares how a challenging monocular patient reinforced the importance of patience, presence, and psychological support in ophthalmic care.

Strategies for treatment intervals, drug selection, and patient expectations.